Comparative analysis of colonic gene expression of three experimental colitis models mimicking inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 13, Issue 3, 2007, Pages 325-330

  Te Velde, Anje A ^a,d   De Kort, Floor ^a   Sterrenburg, Ellen ^b   Pronk, Inge ^a   Ten Kate, Fiebo J W ^a   Hommes, Daniel W ^b,c   Van Deventer, Sander J H ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Netherlands Organisation for Health Research and Development   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

CD45RB transfer; DSS; Experimental colitis; Gene expression; IBD; TNBS

Indexed keywords

CD45RB ANTIGEN;

ANIMAL TISSUE; ARTICLE; CELL POPULATION; COLITIS; CONTROLLED STUDY; CROHN DISEASE; DNA MICROARRAY; ENTERITIS; GENE EXPRESSION; GENETIC ANALYSIS; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA ISOLATION; T LYMPHOCYTE; ULCERATIVE COLITIS;

ANIMALS; ANTIGENS, CD45; COLITIS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; INFLAMMATORY BOWEL DISEASES; MICE; MICE, INBRED BALB C; MICE, SCID; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; T-LYMPHOCYTES; TRINITROBENZENESULFONIC ACID;

EID: 33947492645     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20079     Document Type: Article

References (65)

1. Cobrin GM, Abreu MT. Defects in mucosal immunity leading to Crohn's disease. Immunol Rev. 2005;206:277-295.
2. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3:521-533.
3. Pizarro TT, Arseneau KO, Bamias G, et al. Mouse models for the study of Crohn's disease. Trends Mol Med. 2003;9:218-222.
4. Andreakos E, Foxwell B, Feldmann M. Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? Immunol Rev. 2004;202:250-265.
5. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol. 2002;20:495-549.
6. Camoglio L, te Velde AA, de Boer A, et al. Hapten-induced colitis associated with maintained Th1 and inflammatory responses in IFN-γ gamma receptor-deficient mice. Eur J Immunol. 2000;30:1486-1495.
7. Ishioka T, Kuwabara N, Oohashi Y, et al. Induction of colorectal tumors in rats by sulfated polysaccharides. Crit Rev Toxicol. 1987;17:215-244.
8. Powrie F, Leach MW, Mauze S, et al. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol, 1993;5: 1461-1471.
9. Dieckgraefe BK, Stenson WF, Korzenik, et al. Analysis of mucosal gene expression in inflammatory bowel disease by parallel oligonucleotide arrays. Physiol Genom. 2000;4:1-11.
10. Dooley TP, Curto EV, Reddy SP, et al. Regulation of gene expression in inflammatory bowel disease and correlation with IBD drugs. Screening by microarrays. Inflamm Bowel Dis. 2004;10:1-14.
11. Mannick EE, Bonomolo JC, Horswell R, et al. Gene expression in mononuclear cells from patients with inflammatory bowel disease. Clin Immunol. 2004;112:247-257.
12. Costello CM, Mah N, Hasler R, et al. Dissection of the inflammatory bowel disease transcriptome using genome-wide cDNA microarrays. PLOS Med. 2005;2: 771-787.
13. Turk R, 't Hoen PAC, Sterrenburg E, et al. Gene expression variation between mouse inbred strains. BMC Genom. 2004;5:57-64.
14. Bennink RJ, Hamann J, de Bruin K, et al. Imaging of intestinal neutrophil recruitment with dedicated animal pinhole SPECT in a DSS colitis mouse model. J Nucl Med. 2005;46:526-531.
15. ten Hove T, Drillenburg P, Wijnholds J, et al. Differential susceptibility of multidrug resistance protein-1 deficient mice to DSS and TNBS-induced colitis. Dig Dis Sci. 2002;47: 2056-2063.
16. Van Montfrans C, Rodriguez Pena MS, Pronk I, et al. Prevention of colitis by interleukin 10-transduced T lymphocytes in the SCID mice transfer model. Gastroenterology. 2002;123:1865-1876.
17. Bennink, RJ, van Montfrans C, de Jonge WJ, et al. Imaging of intestinal lymphocyte homing by means of pinhole SPECT in a TNBS colitis mouse model. Nucl Med Biol. 2004;31:93-101.
18. Camoglio L, Juffermans NP, Peppelenbosch M, et al. Contrasting roles of IL-12p40 and IL-12p35 subunits in the development of experimental colitis. Eur J Immunol. 2002;32:261-269.
19. Ten Hove T, Corbaz A, Amitai H, et al. Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-α production. Gastroenterology. 2001;121:1372-1379.
20. Read S, Powrie F. Induction of inflammatory bowel disease in immunodeficient mice by depletion of regulatory T cells. Current Protein Immunol. 1999;15.13.1-15.13.10.
21. Technical note. Rosetta Biosoftware. Re-ratio and Ratio Split processing: Supplement User Information; 2003 Rosetta, Seattle, WA.
22. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B. 1995;57:289-300.
23. Stevens C, Walz G, Singaram C, et al. Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci. 1992;37:818-826.
24. Woywodt A, Ludwig D, Neustock P, et al. Mucosal cytokine expression, cellular markers and adhesion molecules in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 1999;11:267-276.
25. Neurath MF, Fuss I, Schurmann G, et al. Cytokine gene transcription by NF-kappa B family members in patients with inflammatory bowel disease. Ann NY Acad Sci. 1998;859:149-159.
26. Niessner M, Volk BA. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol. 1995;101:428-435.
27. Camoglio L, Te Velde AA, Tigges AJ, et al. Altered expression of interferon-gamma and interleukin-4 in inflammatory bowel disease. Inflamm Bowel Dis. 1998;4:285-290.
28. Agyekum S, Church A, Sohail M, et al. Expression of lymphotoxin-beta (LT-beta) in chronic inflammatory conditions. J Pathol. 2003;199:115-121.
29. Seegert D, Rosenstiel P, Pfahler H, et al. Increased expression of IL-16 in inflammatory bowel disease. Gut. 2001;48:326-332.
30. Autschbach F, Funke B, Katzenmeier M, et al. Expression of chemokine receptors in normal and inflamed human intestine, tonsil, and liver - an immunohistochemical analysis with new monoclonal antibodies from the 8th international workshop and conference on human leucocyte differentiation antigens. Cell Immunol. 2005;236:110-114.
31. Andoh A, Zhang Z, Inatomi O, et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology. 2005;129:969-984.
32. Connor SJ, Paraskevopoulos N, Newman R, et al. CCR2 expressing CD4+ T lymphocytes are preferentially recruited to the ileum in Crohn's disease. Gut. 2004;53:1287-1294.
33. Mazzucchelli L, Hauser C, Zgraggen K, et al. Differential in situ expression of the genes encoding the chemokines MCP-1 and RANTES in human inflammatory bowel disease. J Pathol. 1996;178:201-206.
34. Uguccioni M, Gionchetti P, Robbiani DF, et al. Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am J Pathol. 1999;155:331-336.
35. McCormack G, Moriarty D, O'Donoghue DP, et al. Tissue cytokine and chemokine expression in inflammatory bowel disease. Inflamm Res. 2001;50:491-495.
36. Banks C, Bateman A, Payne R, et al. Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J Pathol. 2003;199:28-35.
37. Wedemeyer J, Lorentz A, Goke M, et al. Enhanced production of monocyte chemotactic protein 3 in inflammatory bowel disease mucosa. Gut. 1999;44:629-635.
38. Chen W, Paulus B, Shu D, et al. Increased serum levels of eotaxin in patients with inflammatory bowel disease. Scand J Gastroenterol. 2001;36:515-520.
39. Jugde F, Alizadeh M, Boissier C, et al. Quantitation of chemokines (MDC, TARC) expression in mucosa from Crohn's disease and ulcerative colitis. Eur Cytokine Netw. 2001;12:468-477.
40. Kwon JH, Keates S, Bassani L, et al. Colonic epithelial cells are a major site of macrophage inflammatory protein 3alpha (MIP-3alpha) production in normal colon and inflammatory bowel disease. Gut. 2002;51:818-826.
41. Kaser A, Ludwiczek O, Holzmann S, et al. Increased expression of CCL20 in human inflammatory bowel disease. J Clin Immunol. 2004;24:74-85.
42. Yuan Y-H, ten Hove T, The FO, et al. Chemokine receptor CXCR3 expression in inflammatory bowel disease. Inflamm Bowel Dis. 2001;7:281-286.
43. Papadakis KA, Prehn J, Zhu D, et al. Expression and regulation of the chemokine receptor CXCR3 on lymphocytes from normal and inflammatory bowel disease mucosa. Inflamm Bowel Dis. 2004;10:778-788.
44. Mitsuyama K, Tsuruta O, Tomiyasu N, et al. Increased circulating concentrations of growth-related oncogene (GRO)-alpha in patients with inflammatory bowel disease. Dig Dis Sci. 2006;51:173-177.
45. Z'Graggen K, Walz A, Mazzucchelli L, et al. The C-X-C chemokine ENA-78 is preferentially expressed in intestinal epithelium in inflammatory bowel disease. Gastroenterology. 1997;113:808-16.
46. Baugh MD, Perry MJ, Hollander AP, et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology. 1999;117:814-822.
47. Louis E, Ribbens C, Godon A, Franchimont D, et al. Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease. Clin Exp Immunol. 2000;120:241-246.
48. von Lampe B, Barthel B, Coupland SE, et al. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut. 2000;47:63-73.
49. Matsuno K, Adachi Y, Yamamoto H, et al. The expression of matrix metalloproteinase matrilysin indicates the degree of inflammation in ulcerative colitis. J Gastroenterol. 2003;38:348-354.
50. Arihiro S, Ohtani H, Hiwatashi N, et al. Vascular smooth muscle cells and pericytes express MMP-1, MMP-9, TIMP-1 and type I procollagen in inflammatory bowel disease. Histopathology. 2001;39:50-59.
51. Wiercinska-Drapalo A, Jaroszewicz J, Flisiak R, et al. Plasma matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 as biomarkers of ulcerative colitis activity. World J Gastroenterol. 2003;9:2843-2845.
52. Lawrance IC, Fiocchi C, Chakravarti S. Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes. Hum Mol Genet. 2001;10:445-456.
53. Dieckgraefe BK, Crimmins DL, Landt V, et al. Expression of the regenerating gene family in inflammatory bowel disease mucosa: Reg I alpha upregulation, processing, and antiapoptotic activity. J Invest Med. 2002;50:421-434.
54. Langmann T, Moehle C, Mauerer R, et al. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology. 2004;127:26-40.
55. Singer II, Kawka DW, Schloemann S, et al. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology. 1998;115:297-306.
56. Salinthone S, Singer CA, Gerthoffer WT. Inflammatory gene expression by human colonic smooth muscle cells. Am J Physiol Gastrointest Liver Physiol. 2004;287:G627-637.
57. Reuter BK, Pizarro TT. Commentary: the role of the IL-18 system and other members of the IL-1R/TLR superfamily in innate mucosal immunity and the pathogenesis of inflammatory bowel disease: friend or foe? Eur J Immunol. 2004;34:2347-2355.
58. Wolk K, Kunz S, Witte E, et al. IL-22 increases the innate immunity of tissues. Immunity. 2004;21:241-254.
59. Keilbaughl SA, Shinl ME, Banchereaul RF, et al. Activation of RegIIIβγ and interferon γ expression in the intestinal tract of SCID mice: an innate response to bacterial colonisation of the gut. Gut. 2005;54:623-629.
60. Nacken W, Roth J, Sorg C, et al. S-100A9/S-100A8: myeloid representatives of the S-100 protein family as prominent players in innate immunity. Microsc Res Tech. 2003;60:569-580.
61. Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA. 1997;94:2031-2035.
62. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol. 1998;161:5733-5744.
63. Martin AR, Villegas I, Alarcon de la Lastra C. The COX-2 inhibitor, rofecoxib, ameliorates dextran sulphate sodium induced colitis in mice. Inflamm Res. 2005;54:145-51.
64. Matuk R, Crawford J, Abreu MT, et al. The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:352-356.
65. Te Velde AA, Verstege MI, Hommes DW. A critical appraisal of the current practice in murine TNBS-induced colitis. Inflamm. Bowel Dis 2006, 12:995-999.